Segall Bryant & Hamill, LLC Halozyme Therapeutics, Inc. Transaction History

Segall Bryant & Hamill, LLC

$7.1 Billion
Q3 2025

A detailed history of Segall Bryant & Hamill, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 216,569 shares of HALO stock, worth $15.2 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares

216,569

Previous 310,830 30.33%

Holding current value

$15.2 Million

Previous $16.2 Million 1.77%

% of portfolio

0.22%

Previous 0.24%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	SELL	$52.92 - $78.28 $4.99 Million - $7.38 Million	-94,261 Reduced 30.33%	216,569 $15.9 Million
Q2 2025 Aug 12, 2025	SELL	$47.91 - $70.14 $1.55 Million - $2.27 Million	-32,341 Reduced 9.42%	310,830 $16.2 Million
Q1 2025 May 02, 2025	SELL	$47.74 - $65.16 $474,153 - $647,169	-9,932 Reduced 2.81%	343,171 $21.9 Million
Q4 2024 Feb 11, 2025	SELL	$42.57 - $61.09 $88,247 - $126,639	-2,073 Reduced 0.58%	353,103 $16.9 Million
Q3 2024 Nov 08, 2024	BUY	$51.3 - $64.42 $2.56 Million - $3.21 Million	49,856 Added 16.33%	355,176 $20.3 Million

Q2 2024 Aug 14, 2024	BUY	$37.81 - $52.4 $1.34 Million - $1.85 Million	35,360 Added 13.1%	305,320 $16 Million
Q1 2024 May 15, 2024	BUY	$33.68 - $41.95 $925,863 - $1.15 Million	27,490 Added 11.34%	269,960 $11 Million
Q4 2023 Feb 14, 2024	BUY	$33.32 - $42.1 $801,845 - $1.01 Million	24,065 Added 11.02%	242,470 $8.96 Million
Q3 2023 Nov 09, 2023	SELL	$36.46 - $44.03 $1.63 Million - $1.97 Million	-44,683 Reduced 16.98%	218,405 $8.34 Million
Q2 2023 Aug 11, 2023	BUY	$30.28 - $38.74 $2.35 Million - $3.01 Million	77,586 Added 41.82%	263,088 $9.49 Million
Q1 2023 May 15, 2023	SELL	$32.86 - $55.7 $44,426 - $75,306	-1,352 Reduced 0.72%	185,502 $7.08 Million
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $7.49 Million - $11.1 Million	186,854 New	186,854 $10.6 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $7.35 Million - $9.87 Million	190,707 New	190,707 $7.54 Million
Q1 2018 May 16, 2018	SELL	$17.06 - $21.2 $228,603 - $284,080	-13,400 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$11.76 - $17.4 $157,584 - $233,159	13,400	13,400 $0

Others Institutions Holding HALO

# of Institutions

669

Shares Held

128M

Call Options Held

599K

Put Options Held

455K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $9.75B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.

Account

Segall Bryant & Hamill, LLC Halozyme Therapeutics, Inc. Transaction History